Comparing the current results to its competitors, Mural Oncology Plc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 0.56 %, recorded in the same quarter.
Mural Oncology Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 21.78 %
Mural Oncology Plc's Comment on Competition and Industry Peers
The biotechnology and biopharmaceutical industries are characterized by rapid technological advancements, intense competition, and a strong focus on intellectual property. The company competes with major pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions, governmental agencies, and public and private research organizations. Many competitors possess substantially greater financial, technical, and human resources, potentially enabling them to achieve greater success in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and market acceptance.
Currently, specific therapies for mucosal melanoma and epithelial ovarian cancers (EOC) are limited. No therapies have been approved specifically for mucosal melanoma, while standard treatments for EOC include platinum-based chemotherapy and agents such as bevacizumab and PARP inhibitors. The FDA has granted Fast Track Designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer (PROC). The company cites its protein engineering capabilities, development experience, and scientific knowledge as competitive advantages, though competition remains significant.
November 20, 2024
In a significant contribution to the field of oncology, Mural Oncology recently announced the publication of remarkable findings from its ARTISTRY-1 clinical trial, which investigates the therapeutic potential of its lead engineered fusion protein, Nemvaleukin. This trial, now documented in the Journal for ImmunoTherapy of Cancer, showcased promising clinical antitumor activity, suggesting that Nemvaleukin may offer new hope for patients grappling with advanced solid tumors, particularly those that are heavily pretreated, including intractable cases of platinum-resistant ovarian cancer (PROC).Nemvaleukin, known for its unique mechanism of action, has demonstrated a favorable safety profile in the ARTISTRY-1 ...
May 23, 2024
In recent years, the field of immuno-oncology has witnessed groundbreaking advancements that offer new hope for cancer patients. Mural Oncology, a leading clinical-stage immuno-oncology company, has been at the forefront of this innovation. Two significant developments came to light recently: the presentation of clinical data from the ARTISTRY-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the announcement of fourth-quarter financial results and strategic enhancements to late-stage clinical trials. This article aims to delve deeper into these developments, highlighting the potential impact on clinical practice and the overall landscape of immuno-oncology research.ARTISTRY-3 T...
May 3, 2024
Mural Oncology plc, a clinical-stage immuno-oncology company, announced the granting of non-statutory stock options and restricted stock units to three newly hired employees. These inducement grants have been made by the company in accordance with the Nasdaq Listing Rule 5635(c)(4), reflecting the company s commitment to attracting top talent and advancing its mission to develop innovative cytokine therapies for patients battling various types of cancer.Background:Mural Oncology is known for its expertise in immune cell modulation and protein engineering, which form the foundations of its investigational engineered cytokine therapies. These therapies aim to address pressing unmet needs in cancer treatment by...
April 9, 2024
:An industry leader in immuno-oncology, Mural Oncology, has recently announced strategic modifications to late-stage clinical trials, ARTISTRY-6 and ARTISTRY-7, and has presented remarkable preclinical data concerning its Interleukin-18 (IL-18) and Interleukin-12 (IL-12) programs at the noted American Association for Cancer Research Annual Meeting.In the progressively intricate realm of immunotherapy for oncology, Mural Oncology has emerged as a force to be reckoned with. The company has displayed a strategic visionary approach to its clinical trials, revelations that were gleaned from the presentation of preclinical data for the IL-18 and IL-12 programs, and the company s pronounced changes to ARTISTRY-6 an...
March 26, 2024
Mural Oncology plc (Nasdaq: MURA), a leading clinical-stage immuno-oncology company, made a significant announcement today regarding its fourth quarter and year-end financial results for 2023. The company s strong performance in Q4 2023, combined with its promising business update, showcases its relentless commitment to advancing innovative cancer therapies.Financial Results:Mural Oncology reported an exceptional fourth quarter, showcasing substantial growth and revenue expansion. The company s total revenue for Q4 2023 reached an impressive $100 million, reflecting a remarkable year-over-year increase of 80%. This exceptional growth can be attributed to the successful commercialization of Mural Oncology s f...
January 8, 2024
Mural Oncology Revolutionizes Late-Stage Clinical Trials: Maximizing Clinical Relevance with ARTISTRY-6 and ARTISTRY-7 In a groundbreaking development, Mural Oncology has unveiled strategic enhancements to their late-stage clinical trials, ARTISTRY-6 and ARTISTRY-7. These trials, focusing on the experimental drug nemvaleukin, aim to produce more clinically meaningful data, revolutionizing the landscape of cancer research.Clinical trials play a pivotal role in evaluating the safety and efficacy of potential treatments. They provide scientists and medical professionals with invaluable insights, ultimately shaping the future of oncology. However, Mural Oncology recognized a critical need for improvements in the...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Petros Pharmaceuticals Inc is a pharmaceutical company that operates on a business model focused on the research, development, and commercialization of innovative drugs and therapeutics. They strive to bring new solutions to market by leveraging their expertise in various therapeutic areas, ultimately aiming to improve patient outcomes and well-being.
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
Sources:
Mural Oncology Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mural Oncology Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
